A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)

NCT01321554 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

392

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Lenvatinib
DRUG: Placebo
DRUG: Lenvatinib

Sponsor

Eisai Inc.